Literature DB >> 2435109

Bone metastasis. Prognosis, diagnosis and treatment.

K Lote, A Walløe, A Bjersand.   

Abstract

Carcinoma of the breast, lung or prostate cause the majority of all bone metastases. Prolonged survival is common in patients with breast or prostate tumours. Different types of treatment may significantly increase the quality of life. Single-dose or fractionated radiation therapy may be effective, and 70 to 90 per cent of patients obtain partial or complete relief from pain. Surgery followed by irradiation is indicated in most patients with pathologic femur fractures. Immediate surgical treatment, either alone or combined with radiation therapy, may prevent paraparesis in patients with incipient cord compression. For neoplasms sensitive to systemic therapy such treatment should often be added to local treatment.

Entities:  

Mesh:

Year:  1986        PMID: 2435109     DOI: 10.3109/02841868609136410

Source DB:  PubMed          Journal:  Acta Radiol Oncol        ISSN: 0349-652X


  12 in total

1.  Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases.

Authors:  Nicholas P Webber; Sunil Sharma; Allie H Grossmann; Akram Shaaban; Kevin B Jones; Lester J Layfield; R Lor Randall
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

2.  Metastatic cancer mimicking mechanical low back pain: a case report.

Authors:  Lance M Mabry; Michael D Ross; John M Tonarelli
Journal:  J Man Manip Ther       Date:  2014-08

Review 3.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.

Authors:  Massimiliano Pacilio; Guido Ventroni; Chiara Basile; Pasquale Ialongo; Domenico Becci; Lucio Mango
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02       Impact factor: 9.236

5.  Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.

Authors:  Jae Ho Chung; Moo Suk Park; Young Sam Kim; Joon Chang; Joo Hang Kim; Sung Kyu Kim; Se Kyu Kim
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

6.  MDA-MB-435 human breast carcinoma metastasis to bone.

Authors:  John F Harms; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.

Authors:  Eleni M Karapanagiotou; Evangelos Terpos; Kalliopi D Dilana; Christina Alamara; Ioannis Gkiozos; Aris Polyzos; Kostas N Syrigos
Journal:  Med Oncol       Date:  2009-04-17       Impact factor: 3.064

8.  Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP.

Authors:  L Bianchi; A Baroli; L Marzoli; C Verusio; C Chiesa; L Pozzi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-28       Impact factor: 9.236

9.  Cancer lung: An unusual presentation.

Authors:  Shankar L Jakhar; Rohitashwa Dana; D P Punia
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

10.  Ossification and increased bone mineral density with zoledronic acid in a patient with lung adenocarcinoma: A case report.

Authors:  Koichi Kurishima; Gen Ohara; Katsunori Kagohashi; Norio Takayashiki; Tomohiro Tamura; Toshihiro Shiozawa; Kunihiko Miyazaki; Mio Kawaguchi; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Exp Ther Med       Date:  2014-08-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.